Heart Health Biotech Kardigan Raises $400 Million in Upsized IPO as Sector Rebounds

Cardiovascular drug developer Kardigan Inc. made a resounding debut on the public markets this week, raising $400 million in an upsized initial public offering. The New Jersey and San Francisco-based biotech priced 25 million shares at $16 each, hitting the absolute top of its marketed range. The stock began trading Thursday on the Nasdaq Global Market under the ticker symbol KARD, marking one of the most anticipated healthcare listings of the year.[1][4]

The massive cash injection caps a meteoric private fundraising run for the startup, which only unveiled itself in early 2025. Prior to the IPO, Kardigan had already amassed nearly $570 million across a $300 million Series A and a $254 million Series B, backed by heavyweight life sciences investors including ARCH Venture Partners, Perceptive Advisors, and Sequoia Heritage. With the public offering complete, the company’s total capitalization approaches $1 billion, giving it an estimated market valuation of roughly $1.4 billion.[2][3][5][6]

Kardigan’s ability to command such a premium stems largely from its leadership team’s proven track record in the notoriously difficult cardiovascular space. CEO Tassos Gianakakos previously helmed MyoKardia, a heart-disease biotech that Bristol Myers Squibb acquired for $13.1 billion in 2020. That acquisition yielded Camzyos, a now-approved blockbuster heart medication. Investors are betting heavily that Gianakakos and his team of former MyoKardia executives can replicate that success with their new venture.[2][3][5]

Rather than discovering new molecules from scratch, Kardigan has built its pipeline by in-licensing promising, partially de-risked assets from major pharmaceutical companies. The company’s lead candidate, danicamtiv, was originally discovered by MyoKardia before the Bristol Myers Squibb buyout. Kardigan licensed the drug back and is now advancing it through Phase 2b/3 trials as a targeted treatment for genetic dilated cardiomyopathy, a severe condition where faulty genes disrupt heart muscle proteins and hinder blood pumping.[2][3][5]

The company’s war chest will also fund two other mid-stage clinical programs. Approximately $80 million to $90 million is earmarked for ataciguat, a daily pill licensed from Sanofi that aims to slow the progression of calcific aortic valve stenosis in patients with moderate disease. Another $40 million to $50 million will support tonlamarsen, a monthly injection derived from Ionis Pharmaceuticals designed to manage acute severe hypertension in patients following hospitalization.[2][5]

Beyond the molecules themselves, Kardigan is attempting to modernize how cardiovascular trials are conducted. The company pairs its experimental medicines with "Prolaio," a proprietary data and analytics platform. By utilizing wearable sensors, real-world patient data, and artificial intelligence-driven analytics, the platform aims to establish digital clinical endpoints and improve trial precision—a critical advantage in heart disease studies, which historically require massive, expensive patient cohorts to prove efficacy.[5][6]

The successful listing serves as a powerful bellwether for the broader biotechnology sector, which is experiencing a dramatic renaissance in 2026 after a multi-year drought. Kardigan is the 13th venture-backed biotech company to go public in the United States this year, already eclipsing the total number of listings seen in all of 2025.[3]

More notably, capital is flowing in massive tranches to companies with late-stage clinical data. Kardigan is the fourth drug startup this year to raise at least $400 million in IPO proceeds, a high-water mark rarely seen since the pandemic-era biotech boom of 2021. The offering follows closely on the heels of Parabilis Medicines’ record-breaking $670 million float and Generate Biomedicines’ $400 million debut earlier in the year.[2][3]

Gianakakos noted that the broader tech market's obsession with artificial intelligence and massive listings—such as SpaceX's recent mega-IPO—has not siphoned capital away from life sciences. Because cardiovascular disease remains the leading cause of death globally, the company's mission resonates easily with both specialized healthcare funds and generalist investors who understand the urgent need for targeted therapies.[2][6]

With the IPO proceeds secured, Kardigan expects its financial runway to extend well into 2028. This timeline is crucial, as it comfortably bridges the company through its most significant upcoming catalysts: topline Phase 2b data readouts for all three of its clinical programs, which are expected in the first half of 2027. If successful, the company plans to commercialize the drugs independently in the United States while laying the groundwork for global partnerships.[2][5]